Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric collapse. Despite strong growth and clinical progress, Nyxoah adjusted its 2026 full-year revenue forecast down to €33-35 million from €36-40 million. The company remains confident in sustained U.S. growth and improving patient care for obstructive sleep apnea.
Nyxoah's preliminary Q3 2026 revenue and adjusted full-year forecast provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Oct 19, 2026 18:43 WIB: Among 150 priced US health stocks, 68 rose and 54 fell today. Notable movers include Recursion Pharmaceuticals Inc (RXRX) at USD 3.56 with a 2.74% gain and a typical hold time of 21 days, Heron Therapeutics Inc (HRTX) at USD 0.37 up 2.49% with a 36-day hold, and Revolution Medicines Inc (RVMD) at USD 181.96 rising 2.25% with a 4-day hold.
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...
